ICAP
RPRX

Independence Capital Asset Partners’s Repros Therapeutics Inc. RPRX Stock Holding History

Independence Capital Asset Partners’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-234,959
Closed -$4.33M – 137
2013
Q2 		$4.33M Buy
+234,959
New +$4.15M 0.76% 48

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Independence Capital Asset Partners's RPRX Position: Q3 2013 in Review

Independence Capital Asset Partners sold out of Repros Therapeutics Inc. (RPRX) in Q3 2013, closing a stake of 234,959 shares — an estimated $4.33M sold.

Independence Capital Asset Partners first reported a position in RPRX in Q2 2013 and held it in 1 quarter. The position peaked at $4.33M in Q2 2013. 92 funds tracked by Wall St. Rank hold RPRX as of Q3 2013.

  • Independence Capital Asset Partners reported no remaining Repros Therapeutics Inc. position as of Q3 2013 after selling out during the quarter.
  • Independence Capital Asset Partners sold 234,959 Repros Therapeutics Inc. shares in Q3 2013, an estimated $4.33M.
  • Independence Capital Asset Partners first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 1 quarter.
  • Independence Capital Asset Partners's Repros Therapeutics Inc. position peaked at $4.33M in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2013.

Based on Independence Capital Asset Partners's 13F filing for Q3 2013, filed 14 Nov 2013.